Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable.

× No keyword cloud information.

86 in total

1. AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Authors: Xinping Yang; Suiyang Liu; Surender Kharbanda; Richard M Stone
Journal: Leuk Res Date: 2011-12-03 Impact factor: 3.156

2. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Authors: Deepa Sampath; Asifa Malik; William Plunkett; Billie Nowak; Betsy Williams; Michelle Burton; Srdan Verstovsek; Stefan Faderl; Guillermo Garcia-Manero; Alan F List; Said Sebti; Hagop M Kantarjian; Farhad Ravandi; Jeffrey E Lancet
Journal: Leuk Res Date: 2013-08-06 Impact factor: 3.156

3. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors: Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal: Clin Cancer Res Date: 2015-02-27 Impact factor: 12.531

4. Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors: Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal: J Med Chem Date: 2020-05-06 Impact factor: 7.446

Review 5. Novel agents for the treatment of childhood acute leukemia.

Authors: Colleen E Annesley; Patrick Brown
Journal: Ther Adv Hematol Date: 2015-04

6. mTOR regulates cell survival after etoposide treatment in primary AML cells.

Authors: Qing Xu; James E Thompson; Martin Carroll
Journal: Blood Date: 2005-09-08 Impact factor: 22.113

7. Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.

Authors: Juana Serrano-López; Josefina Serrano; Vianihuini Figueroa; Antonio Torres-Gomez; Salvador Tabares; Javier Casaño; Noemi Fernandez-Escalada; Joaquín Sánchez-Garcia
Journal: Haematologica Date: 2013-06-28 Impact factor: 9.941

8. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors: Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531

9. Resistance to Trastuzumab in Breast Cancer.

Authors: Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531

10. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Authors: Nicolas Chapuis; Jérôme Tamburini; Pascale Cornillet-Lefebvre; Lucile Gillot; Valérie Bardet; Lise Willems; Sophie Park; Alexa S Green; Norbert Ifrah; François Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal: Haematologica Date: 2009-12-08 Impact factor: 9.941